Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January-March 2021

Daniel Graciaa; Hans P Verkerke; Jeannette Guarner; Ana Maria Moldoveanu; Narayanaiah Cheedarla; Connie M Arthur; Cheryl Maier; Andrew Neish; Sara Auld; Angela Campbell; Neel Gandhi; John Roback; Sarita Shah

About this item:

123 Views | 40 Downloads

Author Notes:

Daniel S. Graciaa, MD, Woodruff Memorial Research Building, 101 Woodruff Circle, Suite 2101, Atlanta, GA 30322. E-mail: dsgraci@emory.edu

This study was supported by an Emory University Woodruff Health Sciences Center CURE Award and by the National Institutes of Health (NIH) National Cancer Institute (grant no. 1U54CA260563-01). S.C.A. was supported by the National Institute of Allergy and Infectious Diseases (NIAID grant no. K23AI134182). N.R.G. was supported in part by the NIAID (grant nos. K24AI114444 and P30AI168386).

All authors report no conflicts of interest relevant to this article.

Subjects:

Keywords:

SARS-CoV-2
blood samples

Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January-March 2021

Daniel Graciaa, Emory University

Hans P Verkerke, Emory University

Jeannette Guarner, Emory University

Ana Maria Moldoveanu, Emory University

Narayanaiah Cheedarla, Emory University

Connie M Arthur, Harvard Medical School

Cheryl Maier, Emory University

Andrew Neish, Emory University

Sara Auld, Emory University

Angela Campbell, Emory University

Neel Gandhi, Emory University

John Roback, Emory University

Sarita Shah, Emory University

Show all authors Show less authors

Tools:

Journal Title:

Antimicrobial Stewardship and Healthcare Epidemiology

Volume:

Volume 2, Number 1

Publisher:

Cambridge University Press | 2022-09-22, Pages e159-e159

Type of Work:

Article | Final Publisher PDF

Permanent URL:

https://pid.emory.edu/ark:/25593/w4691

Publisher DOI:

http://doi.org/10.1017/ash.2022.298

Abstract:

We describe severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG seroprevalence and antigenemia among patients at a medical center in January-March 2021 using residual clinical blood samples. The overall seroprevalences were 17% by infection and 16% by vaccination. Spent or residual samples are a feasible alternative for rapidly estimating seroprevalence or monitoring trends in infection and vaccination.

Copyright information:

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/).

Export to EndNote

Undergraduate

Community

Graduate

Libraries

Library Tools

Resources

Resources

About this item:

Author Notes:

Subjects:

Keywords:

Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January-March 2021

Tools:

Abstract:

Copyright information: